Intraocular Pressure Management in Glaucoma Afflictions

The maintenance of intraocular pressure (IOP) within a narrow range is pivotal to preserving optic nerve integrity in glaucoma, a leading cause of irreversible blindness globally. Elevated IOP exerts mechanical stress and disrupts axonal transport in retinal ganglion cells, precipitating progressive vision loss. Management strategies focus on lowering IOP by reducing aqueous humour production or enhancing its outflow through pharmacological agents, laser trabeculoplasty and surgical interventions. First-line therapy typically comprises topical medications such as prostaglandin analogues, beta-blockers and carbonic anhydrase inhibitors. Laser treatments, notably selective laser trabeculoplasty, offer tissue-sparing augmentation of trabecular outflow, while surgical approaches—including trabeculectomy and aqueous-shunt implantation—are reserved for refractory cases. Recent innovations encompass sustained-release drug delivery systems, nanocarrier formulations, gene therapy and targeted neuroprotection. Concurrently, genetic and molecular discoveries have unveiled novel druggable targets, and emerging biomarkers promise personalised risk stratification. Together, these advances reflect a multidimensional paradigm aimed at maximising efficacy, safety and patient adherence in IOP management.

Research from Nature Portfolio

Recent studies have expanded the molecular framework underlying IOP management and glaucoma progression. Investigations into peripheral blood mononuclear cell respiratory function demonstrated that reduced oxygen consumption rates and lowered nicotinamide adenine dinucleotide levels correlate with accelerated visual field deterioration, even among patients receiving standard IOP-lowering therapy, highlighting systemic biomarkers for monitoring treatment response. Large-scale multitrait genome-wide association analyses have dramatically increased the catalogue of genetic loci linked to intraocular pressure regulation and optic nerve vulnerability. These efforts have identified hundreds of candidate genes amenable to pharmacological modulation, thereby enriching the conventional IOP-centric approach with opportunities for precision-guided therapies.

Intraocular Pressure Management in Glaucoma Afflictions publication trend

The graph below shows the total number of articles in intraocular pressure management in glaucoma afflictions across all publications each year (not limited to Nature Index journals).

Technical terms

Intraocular Pressure (IOP): The fluid pressure inside the eye, the principal modifiable risk factor in glaucoma.

Aqueous Humour: The transparent fluid produced by the ciliary body that maintains IOP and nourishes intraocular tissues.

Trabecular Meshwork: The sieve-like tissue at the iridocorneal angle responsible for the majority of aqueous humour drainage.

Prostaglandin Analogues: Topical agents that lower IOP by increasing uveoscleral outflow.

Selective Laser Trabeculoplasty (SLT): A laser procedure that enhances trabecular outflow by selectively stimulating cellular remodelling without coagulative damage.

Genome-Wide Association Study (GWAS): A method that examines common genetic variants across the genome to identify associations with specific traits, such as IOP.

Peripheral Blood Mononuclear Cell (PBMC): Immune cells whose metabolic function can serve as systemic biomarkers for glaucoma progression.

References

1. Peripheral blood mononuclear cell respiratory function is associated with progressive glaucomatous vision loss. Nature Medicine (2024).
2. Large-scale multitrait genome-wide association analyses identify hundreds of glaucoma risk loci. Nature Genetics (2023).
3. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. The Lancet (2014).
4. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. The Lancet (2019).